Aclaris Therapeutics Q1 EPS $(0.24) Beats $(0.29) Estimate, Sales $2.40M Beat $1.37M Estimate
Aclaris Therapeutics Q1 EPS $(0.24) Beats $(0.29) Estimate, Sales $2.40M Beat $1.37M Estimate
Aclaris Therapeutics第一季度每股收益美元（0.24美元）超过预期（0.29美元），销售额240万美元超过137万美元的预期
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 42.86 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $1.37 million by 75.04 percent. This is a 5.14 percent decrease over sales of $2.53 million the same period last year.
Aclaris Therapeutics（纳斯达克股票代码：ACRS）公布的季度亏损为每股0.24美元，比分析师普遍预期的0.29美元（0.29美元）高出17.24％。与去年同期每股亏损0.42美元（0.42）相比，增长了42.86％。该公司公布的季度销售额为240万美元，比分析师普遍预期的137万美元高出75.04％。这比去年同期的253万美元销售额下降了5.14％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。